High-Protein Diet for Health & Longevity

Created on 10/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

A high-protein diet is an eating pattern supplying protein above the long-standing minimum, mainly to support muscle and healthy aging. It most consistently adds to strength-training muscle gains and helps preserve muscle during weight loss. Healthy kidneys appear to tolerate it; reduced kidney function carries a credible risk of faster decline. Meat-heavy intake is linked to more diabetes. For strength-training adults with normal kidney function, evidence leans toward benefit. (Full Review)

Protocol

General adult target
1.2–1.6 g/kg/day
Per the Dietary Guidelines for Americans 2025–2030; the Recommended Dietary Allowance minimum is 0.8 g/kg/day
Resistance-training approach
About 1.6 g/kg/day
Plateau of training gains; sports-nutrition society range 1.4–2.0 g/kg/day
Single or split doses
3–4 meals, 20–40 g each
Every 3–4 hours, about 0.25 g/kg per meal; older adults about 0.4 g/kg per meal
Time to effect
Lean-mass gains
6+ weeks
With training; the minimum duration in pooled training trials
Satiety
Within days
Modestly greater weight and fat loss in short trials, not confirmed long-term
Triglycerides and blood pressure
Within 6 weeks
Seen in a feeding trial

Benefits

Contraindications
  • CKD stages G3–G5 not on dialysis (eGFR below 60 mL/min/1.73 m²)
  • Phenylketonuria or urea cycle disorders
  • Pregnant women considering high-protein supplement drinks
Key Interactions
  • Levodopa (carbidopa-levodopa): Caution; motor fluctuations
  • CYP1A2 substrates (theophylline; clozapine, tizanidine): Monitor; shortened theophylline half-life (clozapine and tizanidine theoretical)
  • Warfarin (an anticoagulant, a clot-preventing drug): Monitor; lowered INR, weakening anticoagulation
  • Allopurinol (a uric-acid-lowering gout drug): Monitor; risking weaker uric acid lowering
  • Kidney-cleared drugs with narrow margins (lithium, metformin, direct oral anticoagulants (clot-preventing drugs) such as apixaban): Monitor (theoretical); creatinine-based eGFR can mislead dose adjustment
  • NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen): Caution (theoretical) with reduced kidney function
  • Caffeine: Monitor (theoretical); may clear faster
  • Creatine: Monitor (theoretical); falsely lowers creatinine-based eGFR
  • Leucine, HMB (beta-hydroxy-beta-methylbutyrate, a leucine metabolite) and essential amino acid supplements: Monitor (theoretical); may add little above about 1.6 g/kg/day
  • Calcium and vitamin D: Monitor; high-dose calcium may add urinary calcium (theoretical)
  • GLP-1 receptor agonists (injectable appetite-suppressing drugs: semaglutide, tirzepatide): Monitor (theoretical); reduced appetite lowers protein intake
  • Fasting and time-restricted eating (eating only within a daily window, such as 8 hours): Monitor (theoretical); high targets harder to reach
  • Ketogenic diets: Caution (theoretical); excess protein can blunt ketosis

Risk & Side Effects

  • High:
  • Medium: Faster kidney decline with existing kidney impairment; higher type 2 and gestational diabetes risk with animal-protein-heavy intake
  • Low: Cardiovascular disease; midlife mortality and cancer; kidney stone formation; fetal growth restriction in pregnancy; gastrointestinal adverse events
  • Speculative: Adverse colonic metabolite profile

Monitoring

Marker Target Why
eGFR (creatinine and cystatin C) 60 mL/min/1.73 m² or higher Safety check: decline changes or stops use
Urine ACR Below 30 mg/g Safety check: rise signals kidney damage
BUN 7–20 mg/dL Rises with intake, confirming adherence
Uric acid 3.5–7.2 mg/dL Safety check: rise raises gout and stone risk
Fasting triglycerides Below 150 mg/dL Expected change: may fall
HbA1c 4.0–5.6% Safety check: rise flags diabetes risk
IGF-1 No established target; track change from own baseline Expected change: protein raises it
Lean mass (DEXA) No established target; track change from own baseline Expected change: rises or is preserved
24-hour urine calcium (stone formers) 100–300 mg/day Safety check: rise raises stone risk

Cadence: Baseline before raising intake; kidney markers, uric acid and triglycerides 8–12 weeks after reaching the target intake, then every 6–12 months; DEXA every 6–12 months; HbA1c annually. A confirmed eGFR below 60 mL/min/1.73 m², rising albuminuria or a new stone prompts repeat testing within 3 months.

Qualitative Assessment

  • Satiety and hunger between meals
  • Training performance and strength logs
  • Grip strength and ease of rising from a chair
  • Energy levels through the day
  • Digestive comfort, bowel regularity and bloating
  • Sleep quality